{"id":6353,"date":"2011-11-24T10:48:19","date_gmt":"2011-11-24T09:48:19","guid":{"rendered":"http:\/\/www.ilmelanoma.com\/"},"modified":"2026-10-17T11:22:58","modified_gmt":"2026-10-17T10:22:58","slug":"ipilimumab-yervoy","status":"publish","type":"page","link":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/","title":{"rendered":"Ipilimumab in melanoma"},"content":{"rendered":"<div class=\"im26-diagnosis-guide\">\n<aside class=\"im26-dg-related\"><strong>How to read this guide<\/strong><\/p>\n<p>Educational information based on the cited sources, not an individual prescription. Editorial revision is not equivalent to specialist clinical validation. Decisions and treatments must be agreed with the treating team; benefits, risks and availability depend on the case.<\/p>\n<\/aside>\n<nav class=\"im26-dg-toc\" aria-label=\"On this page\"><strong>On this page<\/strong><\/p>\n<ol>\n<li><a href=\"#med-meccanismo\">How it works and what it does not do<\/a><\/li>\n<li><a href=\"#med-ruolo\">From the original trial to current choices<\/a><\/li>\n<li><a href=\"#med-sicurezza\">Immune-mediated effects: report them early<\/a><\/li>\n<li><a href=\"#med-contesti\">Neoadjuvant use, combinations and research<\/a><\/li>\n<\/ol>\n<\/nav>\n<section class=\"im26-dg-section\" id=\"med-meccanismo\">\n<h2>How it works and what it does not do<\/h2>\n<p>Ipilimumab, marketed as Yervoy, is a monoclonal antibody targeting CTLA-4, a regulator of the immune response. Blocking it can promote lymphocyte activity against the tumour. It is neither conventional cytotoxic chemotherapy nor a vaccine, and it does not select a BRAF mutation as its target.<\/p>\n<p>The ability to reactivate an antitumour response also carries a risk of inflammation in healthy tissues. \u201cImmunotherapy\u201d therefore does not mean treatment without important adverse effects. Before starting, discuss autoimmune disease, transplantation, immunosuppressive medication and other relevant health issues with the oncology team.<\/p>\n<div class=\"im26-dg-gallery\">\n<figure><a href=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/monoclonal-antibody-services.jpg\"><img loading=\"lazy\" src=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/monoclonal-antibody-services.jpg\" width=\"350\" height=\"266\" loading=\"lazy\" decoding=\"async\" alt=\"Antibody: an illustrative archive representation, not a depiction of a clinical response.\"\/><\/a><figcaption>Antibody: an illustrative archive representation, not a depiction of a clinical response.<\/figcaption><\/figure>\n<\/div>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yervoy\">EMA \u2014 Yervoy: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.cancer.gov\/types\/skin\/hp\/melanoma-treatment-pdq\">National Cancer Institute \u2014 Melanoma Treatment (PDQ), health professional version<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-ruolo\">\n<h2>From the original trial to current choices<\/h2>\n<p>Hodi and colleagues\u2019 2010 trial demonstrated a survival benefit in previously treated <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/common-types-of-melanoma\/metastatic-melanoma\/\">metastatic melanoma<\/a> and helped change treatment history. It is an important historical reference, but does not by itself describe today\u2019s therapeutic landscape. Indications should not automatically be restricted to people previously given chemotherapy, as older descriptions sometimes suggested.<\/p>\n<p>Today ipilimumab may form part of advanced-melanoma treatment alone or with nivolumab according to the indication. Anti-PD-1 medicines and combinations have changed initial treatment choices. Ten-year CheckMate 067 results show the possibility of durable benefit in some patients without guaranteeing an individual response or making the combination suitable for everyone.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20525992\/\">Hodi et al. \u2014 Ipilimumab, randomized phase 3 (2010)<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39282897\/\">Wolchok et al. \u2014 CheckMate 067, final 10-year outcomes (2024\/2025)<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yervoy\">EMA \u2014 Yervoy: indications, product information and leaflet<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-sicurezza\">\n<h2>Immune-mediated effects: report them early<\/h2>\n<p>Diarrhoea or abdominal pain, blood in stools, jaundice, substantial rash, cough or breathlessness, severe fatigue, unusual headache and vision changes require prompt contact with the team. The bowel, liver, skin, lungs and endocrine glands may be affected, as may other organs. Some toxicities develop after treatment has ended.<\/p>\n<p>The team determines investigations, possible interruption and treatment of adverse effects, which may include corticosteroids or other immunosuppressants. Do not wait for a scheduled appointment when symptoms are new or worsening; in an emergency, seek emergency care and explain which immunotherapy you received. Do not independently change treatment, and retain your treatment documentation.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yervoy\">EMA \u2014 Yervoy: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo\">EMA \u2014 Opdivo: indications and product information<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-contesti\">\n<h2>Neoadjuvant use, combinations and research<\/h2>\n<p>Nivolumab\u2013ipilimumab before surgery has specific evidence, including NADINA. Italy has an AIFA pathway under Law 648\/1996 with defined criteria: this does not mean prescribing it indiscriminately before any operation. The surgical plan and subsequent decisions must remain coordinated by the centre.<\/p>\n<p>Concurrent ipilimumab\u2013<a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\">vemurafenib<\/a> should not be revived as a promising routine treatment: the early study reported hepatotoxicity. New combinations, doses or sequences require their own evidence. When offered in a trial, they must be presented as experimental with a protocol, alternatives and consent; approval of the individual medicines does not automatically make a combination standard.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38828984\/\">Blank et al. \u2014 NADINA, phase 3, NEJM (2024)<\/a>; <a href=\"https:\/\/www.aifa.gov.it\/documents\/20142\/3188844\/Allegato1_Nivolumab_Ipilimumab.pdf\">AIFA \u2014 Nivolumab + ipilimumab, neoadjuvant treatment, Law 648\/1996 (17 November 2025)<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23550685\/\">Ribas et al. \u2014 Hepatotoxicity with vemurafenib + ipilimumab (2013)<\/a>; <a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a>.<\/small><\/p>\n<\/section>\n<aside class=\"im26-dg-related\">\n<h2>Continue reading<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/\">Medical treatment of melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/drugs-approved-for-melanoma\/\">Approved medicines for melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/\">BRAF V600E in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\">Vemurafenib in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/\">Cobimetinib in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/dabrafenib-and-trametinib\/\">Dabrafenib and trametinib in melanoma<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/#med-sperimentali\">Experimental treatments: evidence, limitations and trial access<\/a><\/p>\n<\/aside>\n<section class=\"im26-dg-sources\">\n<h2>Sources and update<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yervoy\">EMA \u2014 Yervoy: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/types\/skin\/hp\/melanoma-treatment-pdq\">National Cancer Institute \u2014 Melanoma Treatment (PDQ), health professional version<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20525992\/\">Hodi et al. \u2014 Ipilimumab, randomized phase 3 (2010)<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39282897\/\">Wolchok et al. \u2014 CheckMate 067, final 10-year outcomes (2024\/2025)<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo\">EMA \u2014 Opdivo: indications and product information<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38828984\/\">Blank et al. \u2014 NADINA, phase 3, NEJM (2024)<\/a><\/li>\n<li><a href=\"https:\/\/www.aifa.gov.it\/documents\/20142\/3188844\/Allegato1_Nivolumab_Ipilimumab.pdf\">AIFA \u2014 Nivolumab + ipilimumab, neoadjuvant treatment, Law 648\/1996 (17 November 2025)<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23550685\/\">Ribas et al. \u2014 Hepatotoxicity with vemurafenib + ipilimumab (2013)<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a><\/li>\n<\/ul>\n<p>Editorial revision and source consultation: 17 October 2026. Study dates distinguish current evidence from historical documents. This date does not certify specialist clinical review.<\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The role of CTLA-4 blockade, combinations with nivolumab and precautions for recognising immune toxicity.<\/p>\n","protected":false},"author":13,"featured_media":0,"parent":5586,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-6353","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipilimumab (Yervoy)<\/title>\n<meta name=\"description\" content=\"Ipilimumab (Yervoy) is a fully human monoclonal antibody that acts by binding to CTLA-4, a membrane protein responsible for inhibiting T lymphocyte activity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipilimumab (Yervoy)\" \/>\n<meta property=\"og:description\" content=\"Ipilimumab (Yervoy) is a fully human monoclonal antibody that acts by binding to CTLA-4, a membrane protein responsible for inhibiting T lymphocyte activity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/\" \/>\n<meta property=\"og:site_name\" content=\"Il Melanoma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-17T10:22:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/monoclonal-antibody-services.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/\",\"name\":\"Ipilimumab (Yervoy)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/11\\\/monoclonal-antibody-services.jpg\",\"datePublished\":\"2011-11-24T09:48:19+00:00\",\"dateModified\":\"2026-10-17T10:22:58+00:00\",\"description\":\"Ipilimumab (Yervoy) is a fully human monoclonal antibody that acts by binding to CTLA-4, a membrane protein responsible for inhibiting T lymphocyte activity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/11\\\/monoclonal-antibody-services.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/11\\\/monoclonal-antibody-services.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/ipilimumab-yervoy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medical treatment of melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ipilimumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"name\":\"Il Melanoma\",\"description\":\"la guida alla conoscenza, prevenzione e cura del melanoma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\",\"name\":\"Il Melanoma\",\"alternateName\":\"ilmelanoma.com\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"width\":300,\"height\":29,\"caption\":\"Il Melanoma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipilimumab (Yervoy)","description":"Ipilimumab (Yervoy) is a fully human monoclonal antibody that acts by binding to CTLA-4, a membrane protein responsible for inhibiting T lymphocyte activity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/","og_locale":"en_US","og_type":"article","og_title":"Ipilimumab (Yervoy)","og_description":"Ipilimumab (Yervoy) is a fully human monoclonal antibody that acts by binding to CTLA-4, a membrane protein responsible for inhibiting T lymphocyte activity.","og_url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/","og_site_name":"Il Melanoma","article_modified_time":"2026-10-17T10:22:58+00:00","og_image":[{"url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/monoclonal-antibody-services.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/","url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/","name":"Ipilimumab (Yervoy)","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/#primaryimage"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/monoclonal-antibody-services.jpg","datePublished":"2011-11-24T09:48:19+00:00","dateModified":"2026-10-17T10:22:58+00:00","description":"Ipilimumab (Yervoy) is a fully human monoclonal antibody that acts by binding to CTLA-4, a membrane protein responsible for inhibiting T lymphocyte activity.","breadcrumb":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/#primaryimage","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/monoclonal-antibody-services.jpg","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/monoclonal-antibody-services.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/"},{"@type":"ListItem","position":2,"name":"Medical treatment of melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/"},{"@type":"ListItem","position":3,"name":"Ipilimumab"}]},{"@type":"WebSite","@id":"https:\/\/www.ilmelanoma.com\/en\/#website","url":"https:\/\/www.ilmelanoma.com\/en\/","name":"Il Melanoma","description":"la guida alla conoscenza, prevenzione e cura del melanoma","publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ilmelanoma.com\/en\/#organization","name":"Il Melanoma","alternateName":"ilmelanoma.com","url":"https:\/\/www.ilmelanoma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","width":300,"height":29,"caption":"Il Melanoma"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/6353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=6353"}],"version-history":[{"count":4,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/6353\/revisions"}],"predecessor-version":[{"id":11117,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/6353\/revisions\/11117"}],"up":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/5586"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=6353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}